Report: 3 drugs to drive breast cancer market in next 10 years

Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/dPduCduTtWCegYhlCidawyCicNWgEn

August 20, 2012 BIO China is an exciting opportunity for your company to explore business prospects in China's emerging biotech industry. Learn more about BIO China on BIOtechNOW. The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.   Today's Top Story  Report: 3 drugs to drive breast cancer market in next 10 years The uptake of ImmunoGen and Genentech's trastuzumab-DM1, Genentech's Perjeta, and Novartis' Afinitor will spur growth in the breast cancer treatment market during the next 10 years, according to an analysis from Decision Resources. Genentech's Herceptin currently leads the $8.6 billion market, but sales may decline over the next decade with the entry of biosimilars, according to the report. MedCityNews.com (8/16)      Earn 2X rewards points on advertising costs with The Business Gold Rewards Card from American Express OPEN. Designed to earn Membership Rewards® points faster: • 3X points on airfare • 2X points on advertising, gas, shipping • 1X points on everything else LEARN MORE AND APPLY   Health Care & Policy  CZ BioMed gains worldwide license to cancer drug patent South Texas Technology Management granted CZ BioMed an exclusive, worldwide license to a U.S. patent covering methods and compositions for a cancer treatment based on oncolytic respiratory syncytial virus activity. The deal is expected to strengthen CZ BioMed's patent line of oncolytic cancer therapies. Pharmaceutical Business Review Online (8/17)      Regulus to collaborate with Biogen to identify MS biomarkers Biogen Idec and Regulus agreed to team up to identify microRNA biomarkers for multiple sclerosis. Biomarkers could be helpful in patient selection in trials, development of companion assays and in tracking MS progression and relapse. The deal entitles Regulus to upfront and milestone fees plus investment by Biogen. Pharmaceutical Business Review Online (8/16)      EMD Millipore in deal with Plasticell over stem cell growth tool EMD Millipore has entered a deal to allow Plasticell to distribute its serum-free stem cell growth medium. EMD has also entered a deal with Ark Therapeutics to develop vaccines. In-PharmaTechnologist.com (8/16)      GSK's mepolizumab is effective against severe asthma in study A Phase IIb trial found that GlaxoSmithKline's injectable humanized monoclonal antibody mepolizumab reduced by almost half the number of attacks in patients with hard-to-treat asthma. The drug might "reduce the need for conventional treatment with oral corticosteroids that can have serious side effects including osteoporosis, high blood pressure and impaired growth in children," lead researcher Ian Pavord said. GSK plans Phase III development by year-end. Reuters (8/16)      DNAtrix gears up for Phase II trial of brain tumor drug DNAtrix is preparing to initiate early next year a midstage trial of Delta-24-RGD, an oncolytic agent designed to eliminate cancer cells without harming healthy cells. The drug, which showed "tremendous efficacy" in a Phase I study, is initially being tested against high-grade glioma, a form of brain tumor. MedCityNews.com (8/17)      Genocea's herpes vaccine goes to Phase I/IIa trial Genocea Biosciences started a Phase I/IIa study to assess the safety and tolerability of vaccine candidate GEN-003 in patients with moderate-to-severe herpes simplex virus-2 infection. The study of about 150 patients also will track the vaccine's effect on the immune system and viral shedding. Pharmaceutical Business Review Online (8/16)        Company & Financial News  NIA marks $1.5M for aging-related molecular studies The National Institute on Aging plans to award $1.5 million next year for research into the molecular and cellular mechanisms that regulate circadian clocks in aging tissue. Projects could receive as much as $200,000 per year for five years. GenomeWeb Daily News (free registration) (8/17)        Featured Content    The Power of Partners Rieva Lesonsky Can You Ban Perfume in Your Workplace? Courtney Rubin Inside a Customer's Head Rory Vaden When Working from Home Isn't Working Carla Young Understanding Your Customers Through Research Denise Lee Yohn   Food & Agriculture  Researchers in China clone cows with tasty trait Researchers from the Beijing University of Agriculture in China have reported breeding two female cloned calves with adipocyte fatty acid binding protein in their meat. The adipocyte fatty acid binding protein is intended to enhance the taste of the meat, a researcher said. Global Times (China) (8/15)        Hot Topics  Top five news stories selected by BIO SmartBrief readers in the past week. Appeals court affirms Myriad Genetics' right to patent cancer genes (Reuters) Life sciences firms raised $1.4 billion in second quarter (MedCityNews.com) Biotech IPOs make return on investments (Xconomy) Roche's Lucentis gets FDA nod as diabetic macular edema therapy (The Wall Street Journal) Scientists print ears, grow muscle at regenerative institute (WXXA-TV (Albany, N.Y.)) Results based on number of times each story was clicked by readers.   Industrial & Environmental  Vilsack: RFS waiver would drive investors away from U.S. biofuels Reviewing the Renewable Fuel Standard in the light of the drought in the Midwest is prudent, but a full or partial waiver would decrease investments in the U.S. biofuels sector, said Agriculture Secretary Tom Vilsack. "My concern is that we send a signal to investors of perhaps less confidence in the industry," said Vilsack, noting that policymakers should wait to see whether the market is responding before making a waiver decision. Bloomberg Businessweek (8/16)      The Buzz(CORPORATE ANNOUNCEMENTS) More than 20 Biotech Companies to Present Business Innovations, Growth Strategies at Mid-Atlantic Bio Interested in learning more about advertising in BIO SmartBrief? Contact Meryl Harold at (202) 407-7828 or mharold@smartbrief.com.    News from BIO  Ship with FedEx FedEx is now offering member companies discounts of up to 35% off select FedEx services, both U.S. and international services. The BIO program with FedEx is one of the many cost-savings programs offered by BIO through its Business Solutions program. There is no charge for BIO member companies to participate in any of the BIO Business Solutions programs -- it is a benefit of membership. Learn more about the BIO and FedEx program.      Learn more about BIO -> Conferences  |  Join BIO  |  Media  |  Issues  |  Industry   SmartQuote  A graceful taunt is worth a thousand insults." --Louis Nizer, American lawyer          This SmartBrief was created for jmabs1@gmail.com   Subscriber Tools       Update account information | Change e-mail address | Unsubscribe | Print friendly format | Web version | Search past news | Archive | Privacy policy Advertise Account Director:  Meryl Harold (202) 407-7828 Download Media Kit   Read more at SmartBrief.com A powerful website for SmartBrief readers including: Industry Home Readers' Choice Search Archive Grab our News Widget Get this RSS Feed Publish your Press Release Download a SmartBrief Mobile app today       Recent BIO SmartBrief Issues: Friday, August 17, 2012 Thursday, August 16, 2012 Wednesday, August 15, 2012 Tuesday, August 14, 2012 Monday, August 13, 2012     Lead Editor:  Tom Parks       Mailing Address: SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004     © 1999-2012 SmartBrief, Inc.® Legal Information